WRIGHT MUST GIVE UP EXCLUSIVE RIGHTS TO MAYO FINGER IMPLANT TECHNOLOGY
This article was originally published in The Gray Sheet
Executive Summary
WRIGHT MUST GIVE UP EXCLUSIVE RIGHTS TO MAYO FINGER IMPLANT TECHNOLOGY held by its recently acquired Orthomet business under a proposed consent decree with the Federal Trade Commission announced Dec. 8. The agreement, which cleared the way for Wright Medical's acquisition of Orthomet, requires Wright to relinquish Orthomet's exclusive rights to finger implant technology developed by the Mayo Foundation so that Mayo can either "find another non- exclusive licensee in addition to Wright" or "grant an exclusive license to an entity other than Wright," according to FTC.
You may also be interested in...
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.